Cancer Immunotherapy
Cancer immunotherapy (CIT) is a type of biological therapy, aiming to improve anti-tumor immune responses with fewer off-target effects than chemotherapy. Several types of immunotherapy include: oncolytic virus therapies, cancer vaccines, cytokine therapies, adoptive cell transfer (ACT), and immune checkpoint inhibitors (ICIs). In particular, ICIs and ACT have obtained immense clinical response, but their efficacy varies from person to person. Immune cells can be harnessed to eliminate tumor cells, such as T cells, B cells, NK cells, and myeloid cells. T cells have potent tumor-killing capability, therefore, a plethora of cancer immunotherapy research have focused on inducing T-cell-mediated anti-tumor responses. CTLA-4 and PD-1 are found on the cell surface of T cells as co-inhibitory receptors. The breakthrough in cancer immunotherapy results from the identification and subsequent targeting of checkpoint mechanisms in T cells with monoclonal antibodies against CTLA-4 and programmed death-ligand 1/programmed death-1 (PD-L1/PD-1).
Several types of cancers (e.g., melanoma, mismatch repair-deficient cancers, bladder cancer, and non-small cell lung cancer) have achieved significant clinical responses in T-cell checkpoint blockade therapies. However, single-mode immunotherapy faces challenges such as low immune response, low tumor infiltration, and complex immunosuppressive tumor microenvironment. Recently, combined therapies based on tumor immunity have received extensive attention in the research of enhancing tumor cells immunogenicity and inhibiting their growth. For example, anti CTLA-4 and PD-1, immune checkpoint blockade (ICB) combined with chemotherapy, anti-angiogenic drugs and kinase inhibitors.
-
Delamanid (Standard)
0 ImagesSynonyms: OPC-67683 (Standard)Delamanid (Standard) is the analytical standard of Delamanid. This product is intended for research and analytical applications. Delamanid, a newer mycobacterial cell wall synthesis inhibitor, inhibits the synthesisi of mucolic acids.
-
CAY10404 (Standard)
0 ImagesCat. No.: HY-121537RCAS No.: 340267-36-9CAY10404 (Standard) is the analytical standard of CAY10404. This product is intended for research and analytical applications. CAY10404 is a potent and selective cyclooxygenase-2 (COX-2) inhibitor with an IC50 of 1 nM and a selectivity index (SI; COX-1 IC50/COX-2 IC50) of >500000. CAY10404 is a potent PKB/Akt and MAPK signaling pathways inhibitor and induces apoptosis in non-small cell lung cancer (NSCLC) cells. CAY10404, a diarylisoxazole, has good analgesic, anti-inflammatory, and anti-cancer activities.
-
Anti-MSLN/Mesothelin (h7D9.v3)
0 ImagesCat. No.: HY-P991315Synonyms: RG7600 antibodyAnti-MSLN/Mesothelin (h7D9.v3) is a human monoclonal antibody (mAb) targeting MSLN. Anti-MSLN/Mesothelin (h7D9.v3) can be used in ovarian cancer, mesothelioma, and pancreatic cancer research.
-
Mazethramycin
0 ImagesCat. No.: HY-129234CAS No.: 68373-96-6Mazethramycin is an antitumor antibiotic that exerts its antitumor effect by interfering with cellular DNA replication and RNA synthesis. Mazethramycin can be used in cancer research.
-
CD73-IN-1 (Standard)
0 ImagesCat. No.: HY-103695RCAS No.: 2132396-40-6
-
Human MITF mRNA
0 ImagesCat. No.: HY-174580Human MITF mRNA encodes the human melanocyte inducing transcription factor (MITF) protein, a transcription factor that contains both basic helix-loop-helix and leucine zipper structural features. MITF could regulate melanocyte development and is also responsible for pigment cell-specific transcription of the melanogenesis enzyme genes.
-
Frenolicin
0 ImagesCat. No.: HY-N14995CAS No.: 10023-07-1Frenolicin is an antibiotic with antibacterial activity. Frenolicin also exhibits cytotoxicity against tumor cells.
-
PB28 dihydrochloride (Standard)
0 ImagesCat. No.: HY-108511RCAS No.: 172907-03-8PB28 dihydrochloride (Standard) is the analytical standard of PB28 (dihydrochloride) (HY-108511). This product is intended for research and analytical applications. PB28 dihydrochloride, a cyclohexylpiperazine derivative, is a high affinity and selective sigma 2 (σ2) receptor agonist with a Ki of 0.68 nM. PB28 dihydrochloride is also a σ1 antagonist with a Ki of 0.38 nM. PB28 dihydrochloride is less affinity for other receptors. PB28 dihydrochloride inhibits electrically evoked twitch in guinea pig bladder and ileum with EC50 values of 2.62 μM and 3.96 μM, respectively. PB28 dihydrochloride can modulate SARS-CoV-2-human protein-protein interaction. PB28 dihydrochloride induces caspase-independent apoptosis and has antitumor activity.
-
Lumiracoxib (Standard)
0 ImagesSynonyms: COX-189 (Standard)Lumiracoxib (Standard) is the analytical standard of Lumiracoxib. This product is intended for research and analytical applications. Lumiracoxib is a potent,selective and orally active COX-2 inhibitor with a Ki value of 0.06 μM. Lumiracoxib acts as a nonselective NSAID with anti-inflammatory, analgesic and antipyretic activities. Lumiracoxib can be used for osteoarthritis and bone cancer research.
-
Antitubercular agent-47
0 ImagesCat. No.: HY-168123CAS No.: 2956713-87-2Antitubercular agent-47 (compund 5C) shows potent activity against tuberculosis and was effective against DS/MDR/XDR clinical isolates.
-
Feudomycin A
0 ImagesCat. No.: HY-Z17187CAS No.: 79466-09-4Synonyms: 13-DeoxydaunorubicinFeudomycin A is an onion ring antibiotic with anti-tumor cell activity.
-
Akrobomycin
0 ImagesCat. No.: HY-129339CAS No.: 89156-94-5Akrobomycin is an anthracycline antibiotic. Akrobomycin shows antimicrobial and antitumor activities.
-
NGI-1 (Standard)
0 ImagesCat. No.: HY-117383RCAS No.: 790702-57-7Synonyms: ML414 (Standard)NGI-1 (Standard) is the analytical standard of NGI-1 (HY-117383). This product is intended for research and analytical applications. NGI-1 (ML414) is a potent oligosaccharyltransferase (OST) inhibitor, directly targeting and blocKing the function of the OST catalytic subunits STT3A and STT3B. NGI-1 is a cell permeable inhibitor and can effectively reduce virus infectivity without affecting cell viability.
-
Trifluridine (Standard)
0 ImagesSynonyms: Trifluorothymidine (Standard); 5-Trifluorothymidine (Standard); TFT (Standard)Trifluridine (Standard) is the analytical standard of Trifluridine. This product is intended for research and analytical applications. Trifluridine (Trifluorothymidine) is an irreversible and orally active thymidylate synthase inhibitor, and thereby suppressing DNA synthesis. Trifluridine is an antiviral molecule used for research of HSV, rhabdovirus and orthopoxvirus infection. Trifluridine induces cell apoptosis and autophagy. Trifluridine is also an anticancer agent used in studies of metastatic colorectal cancer, gastrointestinal tumors.
-
Flavokawain A (Standard)
0 ImagesFlavokawain A is a chalcone compound and an orally active inhibitor of PRMT5 and cytochrome P450. Flavokawain A has anti-inflammatory, anti-tumor, and immunomodulatory effects. Flavokawain A can inhibit the proliferation of tumor cells and induce apoptosis. Flavokawain A can be used in the research of diseases such as bladder cancer.
-
Ceftriaxone sodium hydrate (Standard)
0 ImagesCat. No.: HY-B0712ARCAS No.: 104376-79-6Synonyms: Ro 13-9904 sodium hydrate (Standard)Ceftriaxone (sodium hydrate) (Standard) is the analytical standard of Ceftriaxone (sodium hydrate). This product is intended for research and analytical applications. Ceftriaxone sodium hydrate (Ro 13-9904 sodium hydrate) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone sodium hydrate is a covalent inhibitor of GSK3β with IC50 value of 0.78 μM. Ceftriaxone sodium hydrate is an inhibitor of Aurora B. Ceftriaxone sodium hydrate has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone sodium hydrate can be used in the study of bacterial infections and meningitis.
-
Cantharidic acid
0 ImagesCat. No.: HY-137135CAS No.: 28874-45-5Cantharidic acid is a selective inhibitor for protein phosphatase 2 (PP2A) and protein phosphatase 1 (PP1). Cantharidic acid inhibits cell viability and arrest cell cycle at sub G1 phase, induces apoptosis in cells NPC-39 and HONE-1 through the upregulation of ERK1/2, p38, and JNK1/2 pathway.
-
PD-L1/HDAC-IN-1
0 ImagesCat. No.: HY-172167CAS No.: 2923313-69-1PD-L1/HDAC-IN-1 (Compound 14) is the inhibitor for PD-L1 and HDAC that inhibits PD-1/PD-L1 interaction, HDAC2 and HDAC3 with IC50 of 88.10, 27.98 and 14.47 nM, respectively. PD-L1/HDAC-IN-1 exhibits slight cytotoxicity in MCF-7 (IC50=19.34 μM). PD-L1/HDAC-IN-1 upregulates the expression of PD-L1 and CXCL10, promoting anti-tumour immune response by recruiting T-cell infiltration into TME.
-
QC6352 (Standard)
0 ImagesCat. No.: HY-104048RCAS No.: 1851373-36-8QC6352 (Standard) is the analytical standard of QC6352 (HY-104048). This product is intended for research and analytical applications. QC6352 is an orally active KDM4 inhibitor with anti-tumor and anti-proliferative activity. QC6352 has in vivo inhibitory effects on PDX models of breast and colon cancer and reduces the number of chemoresistant cell populations. QC6352 inhibits KDM4 different isoforms with IC50s of 104 nM (KDM4A), 56 nM (KDM4B), 35 nM (KDM4C), and 104 nM (KDM4D), respectively. QC6352 has moderate inhibitory activity against KDM5 with an IC50 of 750 nM (KDM5B).
